FAMEGLOW plans to establish a joint venture company to develop and sell anti-aging products and solutions
FAMEGLOW has signed a joint venture agreement with NAGAWA Pharmaceutical Co., Ltd and Mirxes Pte Ltd, planning to establish a joint venture company in Hong Kong on October 27, 2025, with a registered capital of HKD 50 million. The joint venture will focus on the research, development, and sales of anti-aging products and solutions, aiming to meet consumer demands for health and beauty, enhance customer loyalty, and establish a competitive advantage in the medical anti-aging field, creating sustainable revenue sources
According to the Zhitong Finance APP, FAMEGLOW (08603) announced that on October 27, 2025, the company entered into a joint venture agreement with NAGAWA Pharmaceutical Co., Ltd and Mirxes Pte Ltd. Under this agreement, the parties agree to establish a joint venture company in Hong Kong with a registered capital of HKD 50 million. Upon establishment, the joint venture company will be owned by the company, Joint Venture Partner I, and Joint Venture Partner II with respective ownership of 75%, 20%, and 5%. The joint venture company intends to invest in and operate research and sales businesses for anti-aging products and solutions in Hong Kong and selected Asia-Pacific countries.
This collaboration aims to address the shift in consumer demand for "healthy lifespan" and "beautiful lifespan," which will significantly enhance customer lifetime value and loyalty. This move marks a transformation from providing external beauty services to offering comprehensive beauty and health solutions. It is expected to unlock numerous cross-selling opportunities, enhance the company's brand image, establish a competitive advantage in the medical anti-aging field, ultimately create sustainable revenue sources, and bring long-term value to shareholders
